Sanofi Reports Positive Results in Phase 3 Trials of Dupixent

   By Stephen Nakrosis

Sanofi (SNY) on Monday reported positive results from a Phase 3 trial of Dupixent, a treatment for patients suffering from severe chronic rhinosinusitis with nasal polyps.

The condition causes severe swelling of the sinus cavities, and may lead to pain, breathing difficulties and a loss of taste and smell.

The company said the two trials, SINUS-24 and SINUS-52, demonstrated Dupixent, or dupilumab, significantly reduced chronic sinus disease. When added to the standard of care nasal spray, the treatment improved nasal polyp size, nasal congestion severity, chronic sinus disease, sense of smell and co-morbid asthma outcomes, Sanofi said.

Overall, rates of adverse events were generally similar between the Dupixent-treated group and placebo, the company said.

-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

February 25, 2019 13:25 ET (18:25 GMT)

Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024